Do you want to visit this external website and leave amgenpro.com.au?
You are now leaving this Amgen Australia website. Amgen Australia assumes no responsibility for, and exercises no control over, the organizations, opinions, or accuracy of the information on the server or website you are redirected to.
Do you want to visit this external website and leave amgenpro.com.au?
You are now leaving this Amgen Australia website. Amgen Australia assumes no responsibility for, and exercises no control over, the organizations, opinions, or accuracy of the information on the server or website you are redirected to.
You can paste this link into an email or message to share this resource with your patient.
Overview EVENITY® (romosozumab)
EVENITY® contains the active ingredient romosozumab. EVENITY® is used to treat osteoporosis in postmenopausal women at high risk of fracture and to increase bone mass in men with osteoporosis at high risk of fracture.
AmgenPro is intended for healthcare professionals in Australia
Login or create an AmgenPro account to access the latest updates on our products, medical resources and patient programs.
-
References:
- BLINCYTO® (blinatumomab) Approved Product Information. Amgen Australia Pty Ltd. Available at: www.amgen.com.au/Blincyto.PI
- Litzow MR et al. N Engl J Med 2024;391:320–33.
